Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2013 Oct 17;30(1):134–140. doi: 10.1007/s12264-013-1390-3

Hyposmia: a possible biomarker of Parkinson’s disease

Qian Xiao 1, Sheng Chen 1, Weidong Le 1,2,✉
PMCID: PMC5562575  PMID: 24136244

Abstract

Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson’s disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD. In addition to the high prevalence, the occurrence of hyposmia may also predict a higher risk of PD. Investigations into hyposmia and its relationship with PD may help elucidate the underlying pathogenic mechanisms. This review provides an update of olfactory dysfunction in PD and its potential as a biomarker for this devastating disease.

Keywords: hyposmia, Parkinson’s disease, olfaction, biomarker

References

  • [1].Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862. doi: 10.1101/cshperspect.a008862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson’s disease. J Neurol. 2008;255:18–32. doi: 10.1007/s00415-008-5004-3. [DOI] [PubMed] [Google Scholar]
  • [3].Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis. 1975;28:493–497. doi: 10.1016/0021-9681(75)90058-2. [DOI] [PubMed] [Google Scholar]
  • [4].Hawkes CH, Shephard BC, Daniel SE. Is Parkinson’s disease a primary olfactory disorder? QJM. 1999;92:473–480. doi: 10.1093/qjmed/92.8.473. [DOI] [PubMed] [Google Scholar]
  • [5].Moran DT, Rowley JC, 3rd, Jafek BW, Lovell MA. The fine structure of the olfactory mucosa in man. J Neurocytol. 1982;11:721–746. doi: 10.1007/BF01153516. [DOI] [PubMed] [Google Scholar]
  • [6].Breer H. Odor recognition and second messenger signaling in olfactory receptor neurons. Semin Cell Biol. 1994;5:25–32. doi: 10.1006/scel.1994.1004. [DOI] [PubMed] [Google Scholar]
  • [7].Carleton A, Rochefort C, Morante-Oria J, Desmaisons D, Vincent JD, Gheusi G, et al. Making scents of olfactory neurogenesis. J Physiol Paris. 2002;96:115–122. doi: 10.1016/S0928-4257(01)00087-0. [DOI] [PubMed] [Google Scholar]
  • [8].Johnson BA, Leon M. Chemotopic odorant coding in a mammalian olfactory system. J Comp Neurol. 2007;503:1–34. doi: 10.1002/cne.21396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Doty RL. Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis. 2012;46:527–552. doi: 10.1016/j.nbd.2011.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Kovács T. Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Res Rev. 2004;3:215–232. doi: 10.1016/j.arr.2003.10.003. [DOI] [PubMed] [Google Scholar]
  • [11].Lledo PM, Gheusi G, Vincent JD. Information processing in the mammalian olfactory system. Physiol Rev. 2005;85(1):281–317. doi: 10.1152/physrev.00008.2004. [DOI] [PubMed] [Google Scholar]
  • [12].Doty RL. Handbook of Olfaction and Gustation. New York: Marcel Dekker; 2003. pp. 165–180. [Google Scholar]
  • [13].Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318:876–880. doi: 10.1056/NEJM198804073181402. [DOI] [PubMed] [Google Scholar]
  • [14].Ondo WG. Restless Legs Syndrome: Diagnosis and Treatment. New York: Informa Healthcare; 2008. pp. 15–29. [Google Scholar]
  • [15].Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson’s disease is not dopaminemediated. Trends Neurosci. 2003;26:215–221. doi: 10.1016/S0166-2236(03)00038-9. [DOI] [PubMed] [Google Scholar]
  • [16].Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. [DOI] [PubMed] [Google Scholar]
  • [17].Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. doi: 10.1016/S0197-4580(02)00065-9. [DOI] [PubMed] [Google Scholar]
  • [18].Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9:13–24. doi: 10.1038/nrneurol.2012.242. [DOI] [PubMed] [Google Scholar]
  • [19].Chaudhuri KR, Naidu Y. Early Parkinson’s disease and nonmotor issues. J Neurol. 2008;255:33–38. doi: 10.1007/s00415-008-5006-1. [DOI] [PubMed] [Google Scholar]
  • [20].Braak H, Bohl JR, Müller CM, Rüb U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord. 2006;21:2042–2051. doi: 10.1002/mds.21065. [DOI] [PubMed] [Google Scholar]
  • [21].Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson’s disease. Mov Disord. 1995;10:282–287. doi: 10.1002/mds.870100309. [DOI] [PubMed] [Google Scholar]
  • [22].Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord. 2004;19:687–692. doi: 10.1002/mds.10713. [DOI] [PubMed] [Google Scholar]
  • [23].Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain. 2002;125:2431–2445. doi: 10.1093/brain/awf251. [DOI] [PubMed] [Google Scholar]
  • [24].Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, et al. Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov Disord. 2009;24:906–914. doi: 10.1002/mds.22464. [DOI] [PubMed] [Google Scholar]
  • [25].Hanson LR, Frey WH., 2nd Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:S5. doi: 10.1186/1471-2202-9-S3-S5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol. 2008;63:7–15. doi: 10.1002/ana.21327. [DOI] [PubMed] [Google Scholar]
  • [27].Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect. 2005;113:1250–1256. doi: 10.1289/ehp.7567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Smithson LJ, Kawaja MD. Microglia/macrophage cells in mammalian olfactory nerve fascicles. J Neurosci Res. 2010;88:858–865. doi: 10.1002/jnr.22254. [DOI] [PubMed] [Google Scholar]
  • [29].Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson’s disease. Neurology. 2013;80:276–281. doi: 10.1212/WNL.0b013e31827deb74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson’s disease. Exp Neurol. 2006;202:391–403. doi: 10.1016/j.expneurol.2006.07.001. [DOI] [PubMed] [Google Scholar]
  • [31].Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, et al. Prevelance of smell loss in Parkinson’s disease-a multicenter study. Parkinsonism Relat Disord. 2009;15:490–494. doi: 10.1016/j.parkreldis.2008.12.005. [DOI] [PubMed] [Google Scholar]
  • [32].Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 2010;19:1633–1650. doi: 10.1093/hmg/ddq038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–1244. doi: 10.1212/WNL.38.8.1237. [DOI] [PubMed] [Google Scholar]
  • [34].Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–173. doi: 10.1002/ana.21291. [DOI] [PubMed] [Google Scholar]
  • [35].Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM. 2010;103:941–952. doi: 10.1093/qjmed/hcq142. [DOI] [PubMed] [Google Scholar]
  • [36].Bohnen NI, Studenski SA, Constantine GM, Moore RY. Diagnostic performance of clinical motor and non-motor tests of Parkinson’s disease: a matched case-control study. Eur J Neurol. 2008;15:685–691. doi: 10.1111/j.1468-1331.2008.02148.x. [DOI] [PubMed] [Google Scholar]
  • [37].Doty RL, Perl DP, Steele JC, Chen KM, Pierce JD, Jr, Reyes P, et al. Odor identification deficit of the Parkinsonism-dementia complex of Guam: equivalence to that of Alzheimer’s and idiopathic Parkinson’s disease. Neurology. 1991;41:77–80. doi: 10.1212/WNL.41.5_Suppl_2.77. [DOI] [PubMed] [Google Scholar]
  • [38].Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand. 1995;91:247–250. doi: 10.1111/j.1600-0404.1995.tb06998.x. [DOI] [PubMed] [Google Scholar]
  • [39].Busenbark KL, Huber SJ, Greer G, Pahwa R, Koller WC. Olfactory function in essential tremor. Neurology. 1992;42:1631–1632. doi: 10.1212/WNL.42.8.1631. [DOI] [PubMed] [Google Scholar]
  • [40].Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–181. doi: 10.1002/ana.20160. [DOI] [PubMed] [Google Scholar]
  • [41].Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94:176–178. doi: 10.1288/00005537-198402000-00004. [DOI] [PubMed] [Google Scholar]
  • [42].Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol. 2003;60:545–549. doi: 10.1001/archneur.60.4.545. [DOI] [PubMed] [Google Scholar]
  • [43].Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22:39–52. doi: 10.1093/chemse/22.1.39. [DOI] [PubMed] [Google Scholar]
  • [44].Kobayashi M, Saito S, Kobayakama T, Deguchi Y, Costanzo RM. Cross-cultural comparison of data using the odor stick identification test for Japanese (OSIT-J) Chem Senses. 2006;31:335–342. doi: 10.1093/chemse/bjj037. [DOI] [PubMed] [Google Scholar]
  • [45].Barz S, Hummel T, Pauli E, Majer M, Lang CJ, Kobal G. Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson’s disease. Neurology. 1997;49:1424–1431. doi: 10.1212/WNL.49.5.1424. [DOI] [PubMed] [Google Scholar]
  • [46].Sobel N, Thomason ME, Stappen I, Tanner CM, Tetrud JW, Bower JM, et al. An impairment in sniffing contributes to the olfactory impairment in Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98:4154–4159. doi: 10.1073/pnas.071061598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47].Frank RA, Dulay MF, Gesteland RC. Assessment of the Sniff Magnitude Test as a clinical test of olfactory function. Physiol Behav. 2003;78:195–204. doi: 10.1016/S0031-9384(02)00965-4. [DOI] [PubMed] [Google Scholar]
  • [48].Tourbier IA, Doty RL. Sniff magnitude test: relationship to odor identification, detection, and memory tests in a clinic population. Chem Senses. 2007;32:515–523. doi: 10.1093/chemse/bjm020. [DOI] [PubMed] [Google Scholar]
  • [49].Baba T, Takeda A, Kikuchi A, Nishio Y, Hirayama K, Haseqawa T, et al. Association of olfactory dysfunction and brain. Metobolism in Parkinson’s disease. Mov Disord. 2011;26:621–628. doi: 10.1002/mds.23602. [DOI] [PubMed] [Google Scholar]
  • [50].Berg D. Is pre-motor diagnosis possible? The European experience. Parkinsonism Relat Disord. 2012;18:S195–S198. doi: 10.1016/S1353-8020(11)70061-X. [DOI] [PubMed] [Google Scholar]
  • [51].Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord. 2012;27:656–665. doi: 10.1002/mds.24985. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES